Clinical Report: Evaluating the Association Between Medications and Aggression in Children
Overview
This study identifies 31 drugs associated with pediatric aggression using the FAERS database.
Background
Aggression in children is a concern impacting mental health and development. Drug-associated aggression can exacerbate existing behavioral issues or emerge after medication exposure. This study leverages the FAERS database to identify medication-related aggression in pediatric populations.
Data Highlights
Drug
Signal Strength (ROR)
Case Volume
ebastine
23.40
N/A
perampanel
17.41
N/A
montelukast
N/A
1,392
Key Findings
31 drugs exhibited positive signals for aggression in pediatric patients.
45.16% of the signals were from nervous system agents, and 32.26% from respiratory agents.
Ebastine and perampanel had the strongest signals for aggression.
Most drugs showed higher adjusted reporting odds ratios (aRORs) in early childhood, except for levetiracetam, which peaked in adolescence.
Females generally exhibited higher risks across most agents.
Median time-to-onset (TTO) varied significantly.
Clinical Implications
Clinicians should be aware of the potential for aggression associated with various medications in pediatric patients, particularly in younger children and females. This necessitates careful monitoring and consideration of demographic-specific risks when prescribing these agents.
Conclusion
The findings from this study highlight the importance of pharmacovigilance in identifying drug-related aggression in children, emphasizing the need for updated regulatory labeling and clinical vigilance.
